secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2024-01-29T23:59:59+00:00
Accession:  0001104659-24-007471
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.02, 2.02, 7.01, 2.05, 2.06, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HOOKIPA reports Roche termination of HB-700 deal, 30% workforce cut, $117.5M cash
--------------------------------------------------------------------------------

- Roche terminates collaboration for HB-700 (KRAS-mutated cancers) effective April 25, 2024; HOOKIPA regains full rights and remains eligible for IND milestone payment.
- Workforce reduction of ~30% (55 employees) approved; expected severance costs ~$1.5M, non-cash impairment of GMP facility $10M-$13M.
- Company to prioritize HB-200 (HPV16+ HNSCC) and Gilead-partnered infectious disease programs; pauses HB-300 and most preclinical research.
- Preliminary cash and equivalents of $117.5M as of Dec 31, 2023 (unaudited); company expects to conserve resources.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000110465924007471/0001104659-24-007471-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000110465924007471/tm244291d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-007471

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer